» Articles » PMID: 31864099

The Role of Clinical Assessment and Electrophysiology Study in Brugada Syndrome Patients with Syncope

Overview
Journal Am Heart J
Date 2019 Dec 22
PMID 31864099
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Cardiogenic syncope in Brugada syndrome (BrS) increases the risk of major events. Nevertheless, clinical differentiation between cardiogenic and vasovagal syncope can be challenging. We characterized the long-term incidence of major events in a large cohort of BrS patients who presented with syncope.

Methods: From a total of 474 patients, syncope was the initial manifestation in 135 (28.5%) individuals (43.9 ± 13.9 years, 71.1% male). The syncope was classified prospectively as cardiogenic, vasovagal, or undefined if unclear characteristics were present. Clinical, electrocardiographic, genetic, and electrophysiologic features were analyzed. Cardiogenic syncope, sustained ventricular arrhythmias, and sudden death were considered major events in follow-up.

Results: In 66 patients (48.9%), the syncope was cardiogenic; in 51 (37.8%), vasovagal and in 18 (13.3%); undefined. The electrophysiology study (EPS) inducibility was more frequent in patients with cardiogenic syncope and absent in all patients with undefined syncope (28 [53.8%] vs 5 [12.2%] vs 0 [0%]; P < .01). During follow-up (7.7 ± 5.6 years), only patients with cardiogenic syncope presented major events (16 [11.9%]). Among patients with inducible EPS, 7 (21.2%) presented major events (P = .04). The negative predictive value of the EPS for major events was 92.4%. The incidence rate of major events was 2.6% person-year. Parameters associated with major events included cardiogenic syncope (hazard ratio [HR] 6.3; 95% CI 1.1-10.4; P = .05), spontaneous type 1 electrocardiogram (HR 3.7; 95% CI 1.3-10.5; P = .01), and inducible EPS (HR 2.8; 95% CI 1.1-8.8; P = .05).

Conclusions: An accurate syncope classification is crucial in BrS patients for risk stratification. In patients with syncope of unclear characteristics, the EPS may be helpful to prevent unnecessary implantable cardioverter defibrillators.

Citing Articles

Implantable loop recorders in patients with Brugada syndrome: the BruLoop study.

Bergonti M, Sacher F, Arbelo E, Crotti L, Sabbag A, Casella M Eur Heart J. 2024; 45(14):1255-1265.

PMID: 38445836 PMC: 10998731. DOI: 10.1093/eurheartj/ehae133.


Clinical Management of Brugada Syndrome: Commentary From the Experts.

Cutler M, Eckhardt L, Kaufman E, Arbelo E, Behr E, Brugada P Circ Arrhythm Electrophysiol. 2023; 17(1):e012072.

PMID: 38099441 PMC: 10824563. DOI: 10.1161/CIRCEP.123.012072.


Arrhythmic syncope: From diagnosis to management.

Francisco Pascual J, Jordan Marchite P, Rodriguez Silva J, Rivas Gandara N World J Cardiol. 2023; 15(4):119-141.

PMID: 37124975 PMC: 10130893. DOI: 10.4330/wjc.v15.i4.119.


ICD shocks and complications in patients with inherited arrhythmia syndromes.

Siskin M, Cerrone M, Shokr M, Aizer A, Barbhaiya C, Dai M Int J Cardiol Heart Vasc. 2021; 37:100908.

PMID: 34765721 PMC: 8569698. DOI: 10.1016/j.ijcha.2021.100908.